



Achillion Pharmaceuticals  
Investor Relations Department  
300 George St.  
New Haven, CT 06511  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: ACHN**

|               |   |
|---------------|---|
| Last Trade:   | 2.99  |
| Trade Time:   | 3:59 PM ET<br>Jan 19, 2018                          |
| Change:       | 0.04 <span style="color: green;">↑</span> (+1.186%) |
| Day Range     | 2.84 - 2.99   |
| 52-Week Range | 2.69 - 5.66   |
| Volume        | 1,597,427   |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

### Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

*Dec 20, 2017*  
[Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D](#)

*Dec 18, 2017*  
[Achillion Announces ACH-4471 Granted Orphan Drug Designation for the Treatment of C3 Glomerulopathy \(C3G\) and the Initiation of a Phase 1 Extended-Release Bioavailability Study](#)

*Nov 15, 2017*  
[Achillion Announces Pricing of Secondary Offering Of Common Stock](#)

*Nov 14, 2017*  
[Achillion Announces Proposed Secondary Offering of Common Stock](#)

*Nov 14, 2017*  
[Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G](#)

### Upcoming Events [\[ View all \]](#)

*Feb 14, 2018 11:30 AM ET*  
[LEERINK Partners 7th Annual Global Healthcare Conference](#)

### Financial Disclosures [\[ View all \]](#)

#### [Third Quarter Financial Results](#)

*Feb 23, 2017*  
[Annual Report \(10-K\)](#)

*Apr 17, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Nov 1, 2017*  
[Quarterly Report \(10-Q\)](#)

*Aug 8, 2017*  
[Quarterly Report \(10-Q\)](#)

*May 4, 2017*  
[Quarterly Report \(10-Q\)](#)